Article
03 Nov 2025
M&A Amid Trade Uncertainty: Negotiation, Drafting And Strategy
Brad Schneider
Popular Topics
Corporate/Commercial Law
Brad Schneider’s articles from Fasken are most popular:
- with readers working within the Law Firm industries
- within Corporate/Commercial Law topic(s)
- in Canada, North America and Asia
AUTHORS CONTENT
Article
30 Jul 2025
Private Equity Exits: When Might Seeking Term-End Liquidity Create A Conflict?
Article
19 Jun 2025
Rare Earnout Ruling Gives Guidance (And Raises Questions) For M&A
Article
11 Apr 2025
Fasken's Guide To Earnouts In Private M&A
Article
05 Mar 2025
How The Moelis DGCL Amendments Moved Delaware And Canada (A Little) Closer Together: What U.S. Private Equity And Venture Capital Should Know
Article
18 Feb 2025
Private M&A's Long Wait Is Over: New ABA Canadian Private M&A Deal Point Study Released
Article
05 Nov 2024
When Might Shareholders Attract Fiduciary Duties Under A Shareholder Agreement? Guidance From Delaware Relevant To Private Equity And Venture Capital In Canada
Article
19 Jan 2024
Fasken M&A Year In Review 2023
Article
27 Dec 2023
The Advantages Of The ABCA For Canadian Venture Capital, Private Equity And Startups
Article
21 Nov 2023
Delaware's Corporate Opportunity Waiver Comes To Canada: Takeaways For U.S. Private Equity And Cross-Border M&A
Article
20 Nov 2023
The Advantages Of Incorporation Under The Alberta Business Corporations Act
Article
16 May 2023
2022 Canadian PIPE Deal Point Study
Article
18 Oct 2022
Private Equity 2022
Article
22 Apr 2022
Promoting Hydrogen In Canada: Cross-Country Check-Up
Article
31 Mar 2022
Key Takeaways From The ABA US Private M&A Deal Points Study
Article
25 May 2021
2020 Canadian PIPE Deal Point Study
Article
29 May 2020
Large Employer Emergency Financing Facility (LEEFF)
Article
20 May 2020
COVID-19 Access To Credit For Large-Cap Energy Companies
Article
13 May 2020
Update: Agri-Relief: Initiatives For Producers, Agribusinesses And Food Producers
Article
28 Apr 2020
Aid Package To The Canadian Oil And Gas Industry In Response To COVID-19